A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses.

The inclusion of MIP-3α in the vaccine formulation did, however, have a highly significant effect on the ability of IN immunization to recruit T cells to the lung ( Figure 3A ).

also in 132,142 other papers